KR101997023B1 - Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof - Google Patents

Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof Download PDF

Info

Publication number
KR101997023B1
KR101997023B1 KR1020180151614A KR20180151614A KR101997023B1 KR 101997023 B1 KR101997023 B1 KR 101997023B1 KR 1020180151614 A KR1020180151614 A KR 1020180151614A KR 20180151614 A KR20180151614 A KR 20180151614A KR 101997023 B1 KR101997023 B1 KR 101997023B1
Authority
KR
South Korea
Prior art keywords
weight
hydrangea
extract
concentration
mixture
Prior art date
Application number
KR1020180151614A
Other languages
Korean (ko)
Inventor
김성문
송지은
김민주
조택상
김대선
손하라라잔 칸다사미
Original Assignee
강원대학교산학협력단
주식회사 팜크로스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강원대학교산학협력단, 주식회사 팜크로스 filed Critical 강원대학교산학협력단
Priority to KR1020180151614A priority Critical patent/KR101997023B1/en
Application granted granted Critical
Publication of KR101997023B1 publication Critical patent/KR101997023B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/31Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00Processes
    • A23V2300/14Extraction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a Hydrangea macrophylla extract-mixed composition for concentration and tension relief, a health functional food for concentration and tension relief containing the Hydrangea macrophylla extract-mixed composition, a method for manufacturing the Hydrangea macrophylla extract-mixed composition showing effectiveness in concentration and tension relief, and a Hydrangea macrophylla extract mixture showing effectiveness in concentration and tension relief prepared by the method. The Hydrangea macrophylla extract-mixed composition induces a decrease in a relative high beta (RHB) power spectrum in the left prefrontal lobe, when a user takes the Hydrangea macrophylla extract mixture, thereby exhibiting effectiveness in concentration and tension relief.

Description

긴장 및 집중 완화용 수국 추출 혼합 조성물 및 이의 용도{Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof}Hydrangea extract blend composition for tension and intensive alleviation and use thereof -

본 발명은 긴장 및 집중 완화용 수국 추출 혼합 조성물, 상기 수국 추출 혼합 조성물을 포함하는 긴장 및 집중 완화용 건강기능식품, 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물의 제조방법 및 상기 방법으로 제조된 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물에 관한 것이다.The present invention relates to a hydrangea extract mixed composition for tense and concentration alleviation, a health functional food for stress and intensive alleviation comprising the hydrangea extract mixed composition, a method for producing a hydrangea extract mixture having a tension and concentration alleviating effect, And an extracting mixture of hydrangeas having a concentration alleviating effect.

뇌파는 인간 두뇌의 신경세포간의 활동에 의해서 발생한 율동적인 전기현상으로 대뇌피질 표면을 덮고 있는 조직, 두개골, 두피 등을 매개로 두피 위에 넓게 전해지며, 일반적으로 인간의 대뇌피질에서는 각성이나 수면상태에서도 항상 전위변동이 일어나고 있다. 대뇌피질의 신경세포로부터 발생된 미세한 전기활동은 두피 위에 전극을 부착하고, 두뇌에서 발생된 전기신호를 뇌파계에 입력시켜 시간에 따른 전위를 기록하여 측정할 수 있는데 이를 뇌전도(electroencephalogram, EEG)라고 한다. EEG is a rhythmic electrical phenomenon caused by the interaction between the nervous cells of the human brain, which is widely spread on the scalp through the tissues covering the surface of the cerebral cortex, the skull, and the scalp. Generally, in the human cerebral cortex, Potential fluctuations are always occurring. Electroencephalograms (EEGs) can be measured by attaching electrodes on the scalp and inputting electrical signals generated by the brain into the brain waves to record the potentials over time. do.

EEG는 시시각각으로 변화하는 뇌 활동의 변동을 시공간적으로 기록할 수 있고 비침습적, 연속적으로 간단하게 뇌의 기능을 측정할 수 있다는 장점이 있어서 뇌활동기록, 질병진단, 수면연구, 심리치료와 같은 인지과학, 의학, 약학 분야에서 폭넓게 활용되고 있다.EEG is able to record temporal and spatial changes of brain activity changing instantaneously, and it has the merit of being able to easily measure brain function non-invasively, consecutively, so that it can be used for brain activity record, diagnosis of disease, sleep study, Science, medicine, and medicine.

인간의 뇌파는 델타파(0.5~3Hz), 세타파(4~7Hz), 알파파(8~13Hz), 베타파(14~30Hz), 감마파(30Hz 이상)로 구분된다. 뇌파 중 알파파는 기본파로 표현되며 주파수는 8~13Hz이고, 진폭은 10~150V로 정상 성인의 각성, 안정, 폐안 상태에서 보인다. 알파파는 주파수 영역에 따라 slow 알파파(7~8Hz), mid 알파파(9~11Hz), fast 알파파(12~13Hz)로 구분된다.Human brain waves are divided into delta waves (0.5 to 3 Hz), theta waves (4 to 7 Hz), alpha waves (8 to 13 Hz), beta waves (14 to 30 Hz) and gamma waves (30 Hz and more). In EEG, alpha waves are expressed as fundamental waves, frequency is 8 ~ 13Hz, amplitude is 10 ~ 150V, and it is seen in normal adult arousal, stable, and closed state. Alpha waves are divided into slow and fast (7 ~ 8Hz), midal (9 ~ 11Hz) and fast (12 ~ 13Hz) depending on frequency.

Slow 알파파는 긴장이 풀려 있고, 잠들거나 휴식하면서 뇌가 집중하고 있는 상태에서 발생한다. 즉, 휴식에 대한 집중이지만 이것은 활동정지가 아니라 에너지를 보급하면서 언제든지 활동할 수 있는 상태를 유지하는 것이라 할 수 있다.Slow Alpha waves occur when the brain is concentrated while being relaxed, falling asleep, or resting. In other words, it is focused on rest, but it can be said that it is not stopping the activity, but maintaining the state that can act at any time while supplying energy.

Mid 알파파는 평상시의 사고 집중 상태로 긴장을 수반하지 않는 특징을 가지며, 명상, 창조적인 활동, 혹은 뇌에 새로운 정보나 지식을 효율적으로 주입할 때 나타나는 것으로 알려져 있다.The Mid Alpha is characterized by the usual concentration of accidents and does not involve tension, and is known to occur when meditation, creative activity, or efficient injection of new information or knowledge into the brain.

Fast 알파파는 극도로 긴장하여 무엇인가에 집중되어 있을 때 나타나는데 뇌는 반복 활동을 계속하는데 그 일에 집중하는 나머지 다른 것을 생각할 여유가 없으며 다른 신호나 자극에 반응하지 못한다. Fast Alpha Wave It appears when you are extremely nervous and focused on something. The brain keeps repeating, concentrating on it, can not afford to think of anything else, and does not respond to other signals or stimuli.

베타파는 14~30 Hz의 속파(fast wave)로, 5~10V의 낮은 진폭을 가지며, 일반적인 작업을 하거나 의식적인 행동을 할 때 나타나며 정보처리와 같은 정신활동이 있을 때 활성화된다.Beta waves are fast waves of 14 to 30 Hz, have low amplitudes of 5 to 10 V, appear when doing normal work or conscious actions, and are activated when there is mental activity such as information processing.

주파수 영역에 따라 slow 베타파(12-15Hz), mid 베타파(15-20Hz), high 베타파(20-30Hz)로 구분된다. Slow 베타파는 SMR(sensory motor rhythm)파라고도 하며 신체의 움직임이 없는 운동감각 피질의 활동을 최소화한 상태에서 주의를 기울이는 비교적 단순한 과제를 수행할 때 나타난다.It is divided into slow beta waves (12-15Hz), mid beta waves (15-20Hz) and high beta waves (20-30Hz) depending on the frequency domain. The Slow beta wave appears when performing a relatively simple task of paying attention while minimizing the activity of the motor sensory cortex, which is a sensory motor rhythm (SMR) paradigm.

Mid 베타파는 계산이나 암산과 같이 특정한 주제에 집중하면서 비교적 정신부하가 높은 사고활동을 수행할 때 나타난다. High 베타파는 비교적 복잡한 추론이나 정신부하가 높은 편인 복잡한 정보처리 활동을 수행하거나 혹은 정서적인 긴장, 불안, 흥분상태에서 우세해진다. 적당한 긴장 속에 일상 행동을 하고 있을 때 주로 베타파가 발생하여 일을 효과적으로 처리하지만, 스트레스가 심하여 지나친 긴장으로 흥분하게 되면 high 베타파가 발생한다.Mid Beta waves appear when you perform a relatively mental stressful activity while focusing on a specific topic, such as calculations or mental arithmetic. High Beta waves perform relatively complicated reasoning or complex information processing activities with high mental load, or become predominant in emotional tension, anxiety, and excitement. When you are in normal tension with proper tension, you usually get a beta wave, which works effectively, but when you are stressed and over-excited by tension, you get high beta waves.

수국(학명 Hydrangea macrophylla var. thunbergii)은 쌍떡잎식물 장미목 범의귀과의 낙엽관목으로 줄기는 높이 70 cm 정도로서 잎에 단맛이 있다. 꽃은 초여름에 피며 처음에는 푸른색이나 나중에는 홍색이 되며 중심부는 양성화이다. 주변부는 꽃받침이 변한 장식화로 둘러져 있다. 우리나라에서 일교차가 큰 해발 700 m의 강원도 강릉 고산지대에서 많이 자라며 경상남도 지역에서도 많이 재배된다. 신선한 잎에는 필로둘신(phyllodulcin)이 8-베타-글루코사이드의 형태로 들어 있어 단맛이 없으나 건조과정에서 효소 작용으로 분해되어 단맛을 내는 것으로 보고되어 있다. 필로둘신은 부드러운 단맛과 은은한 박하향이 어우러진 것이 특징이다.Hydrangea (Scientific name Hydrangea macrophylla var. Thunbergii) is a deciduous shrub of a dicotyledonous roe-mallow. Its stem is about 70 cm high and has sweetness on leaves. Flowers bloom in early summer, initially blue, then red, and the center is bisexual. The periphery is surrounded by ornaments with calyx. It grows much in Gangneung alpine region of Gangwon-do, 700m above sea level, and it is cultivated in Gyeongsangnam-do region. Fresh leaves contain phyllodulcin in the form of 8-beta-glucoside, which is not sweet but has been reported to be decomposed by enzymatic action in the drying process to produce a sweet taste. Pillow two gins are characterized by a soft sweetness and a soft peppermint.

수국에 함유된 히드란그산(hydrangenic acid), 툰베르기놀(thunberginol), 히드란게놀 4'-O-글루코시드(hydrangenol 4'-O-glucoside)는 구강세균에 대한 항균성과 항알러지성, 항당뇨성에 효과가 있는 것으로 알려져 있으며 수국은 식품의약품안전처의 식품원재료에 등재된 식물로 잎을 식용으로 사용가능하므로 특별한 독성시험 없이 사용이 가능한 안전한 식품원료이기에 스트레스로 인한 긴장 완화에 도움이 되는 기능성을 가지고 있다.Hydrangenic acid, thunberginol and hydrangenol 4'-O-glucoside in hydrangea are antimicrobial and anti-allergic to oral bacteria, It is known that it is effective for diabetic effect. Hydrone is a plant listed in food raw material of food and drug safety department. Because leaf can be used for food, it is safe food raw material that can be used without special toxicity test. Lt; / RTI >

한국등록특허 제1492074호에는 수국 추출물을 유효성분으로 함유하는 피부 미백용 조성물이 개시되어 있고, 한국등록특허 제1719162호에는 수국 추출물을 함유하는 알코올성 신경정신질환 예방 및 치료용 조성물이 개시되어 있으나, 본 발명의 긴장 및 집중 완화용 수국 추출 혼합 조성물과는 상이하다.Korean Patent No. 1492074 discloses a composition for skin whitening comprising an extract of hydrangea as an active ingredient and Korean Patent No. 1719162 discloses a composition for the prevention and treatment of alcoholic psychiatric disorders containing hydrangea extract, And is different from the hydroentangling mixed composition for relaxation and concentration alleviation of the present invention.

본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명자들은 수국 추출 혼합 조성물을 이용하여 뇌파 변화를 분석한 결과, 본 발명의 수국 추출 혼합 조성물은 좌측 전전두엽에서 RHB(Relative High Beta Power Spectrum)의 감소를 유도하는 것을 확인함으로써, 본 발명을 완성하였다.As a result of analyzing EEG changes using the hydrangea extract compound composition, the inventors of the present invention found that the hydrangea extract mixed composition of the present invention can be applied to the left prefrontal cortex of RHB (Relative High Beta Power Spectrum) , Thereby completing the present invention.

상기 과제를 해결하기 위해, 본 발명은 수국(Hydrangea macrophylla) 추출 분말, 결정 셀룰로오스, 유당, 스테아린산마그네슘, 이산화규소, 히드록시프로필메틸 셀룰로오스, 카라멜 색소, 이산화티타늄 및 글리세린을 혼합한 혼합물을 유효성분으로 함유하는 긴장 및 집중 완화용 수국 추출 혼합 조성물을 제공한다.In order to solve the above-described problems, the present invention provides a pharmaceutical composition comprising as an active ingredient a mixture of Hydrangea macrophylla extract powder, crystalline cellulose, lactose, magnesium stearate, silicon dioxide, hydroxypropyl methylcellulose, caramel colorant, titanium dioxide and glycerin The present invention provides a hydrangea extract blending composition for relaxation and concentration alleviation which comprises

또한, 본 발명은 상기 수국 추출 혼합 조성물을 포함하는 긴장 및 집중 완화용 건강기능식품을 제공한다.In addition, the present invention provides a health functional food for stress and concentration alleviation comprising the hydrated extractive mixed composition.

또한, 본 발명은 (a) 수국차에 주정을 첨가하여 출한 후 여과 및 농축하고 건조하여 수국(Hydrangea macrophylla) 추출 분말을 준비하는 단계; 및 (b) 수국 추출 혼합물 총 중량 기준으로, 상기 (a)단계의 준비한 수국 추출 분말과 결정 셀룰로오스, 유당, 스테아린산마그네슘, 이산화규소, 히드록시프로필메틸 셀룰로오스, 카라멜 색소, 이산화티타늄 및 글리세린을 혼합하는 단계를 포함하는 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물의 제조방법을 제공한다.The present invention also relates to a method for preparing a hydrangea macrophylla extract, comprising the steps of: (a) adding a spirit to a hydrangea tea extract, filtering, concentrating and drying the hydrangea extract to prepare Hydrangea macrophylla extract powder; And (b) mixing the hydrated extract powder prepared in the step (a) with crystalline cellulose, lactose, magnesium stearate, silicon dioxide, hydroxypropylmethyl cellulose, caramel colorant, titanium dioxide and glycerin Wherein the hydrangea extract mixture has a stress and concentration alleviating effect.

또한, 본 발명은 상기 방법으로 제조된 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물을 제공한다.In addition, the present invention provides a hydrangea extract mixture having the stress and concentration alleviating effect produced by the above method.

본 발명의 수국 추출 혼합 조성물은 수국 추출 혼합물 섭취를 통해, 좌측 전전두엽에서 RHB(Relative High Beta Power Spectrum)의 감소를 유도하여 긴장 및 집중 완화 효과를 얻을 수 있다. 또한, 본 발명의 수국 추출 혼합 조성물을 식품에 첨가하여 긴장 및 집중 완화를 유도하는 건강기능식품의 개발에 사용될 수 있다.The hydronephritic extraction mixed composition of the present invention can induce reduction of Relative High Beta Power Spectrum (RHB) in the left prefrontal cortex through ingestion of hydrangea extract mixture to obtain a tension and concentration relaxation effect. In addition, the hydrangea extract mixed composition of the present invention can be added to food to be used for the development of a health functional food which induces relaxation and concentration relaxation.

도 1은 수국 추출 분말의 툰베르기놀(thunberginol) C 함량을 HPLC로 분석한 결과를 보여준다.
도 2는 뇌파 측정을 위해 인간의 두뇌에 전극을 붙이는 부위를 제시한 10-20 국제표준 전극부착법을 보여주는 사진이다.
도 3은 피험자의 두뇌에 EGG용 모자를 씌우고 뇌파를 측정하는 모습을 보여주는 사진이다.
FIG. 1 shows the results of HPLC analysis of the content of thunberginol C in the hydrangea extract powder.
FIG. 2 is a photograph showing a 10-20 international standard electrode attaching method showing a region where an electrode is attached to a human brain for EEG measurement.
FIG. 3 is a photograph showing an EGG cap placed on a subject's brain and measuring brain waves.

본 발명의 목적을 달성하기 위하여, 본 발명은 수국(Hydrangea macrophylla) 추출 분말, 결정 셀룰로오스, 유당, 스테아린산마그네슘, 이산화규소, 히드록시프로필메틸 셀룰로오스, 카라멜 색소, 이산화티타늄 및 글리세린을 혼합한 혼합물을 유효성분으로 함유하는 긴장 및 집중 완화용 수국 추출 혼합 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides a method for producing a mixture of hydrangea macrophylla extract powder, crystalline cellulose, lactose, magnesium stearate, silicon dioxide, hydroxypropyl methylcellulose, caramel colorant, titanium dioxide and glycerin As a component of the hydrangea extract mixture composition for relaxation and concentration relaxation.

본 발명의 수국 추출 혼합 조성물에서, 상기 혼합물은 구체적으로는 수국차에 60~70%(v/v) 주정을 8~12배(v/w) 첨가한 후 50~70℃에서 1~3시간씩 1~3회 추출한 후 여과 및 농축하고 건조한 수국(Hydrangea macrophylla) 추출 분말 48~52 중량%, 결정 셀룰로오스 40~45 중량%, 유당 1.8~2.2 중량%, 스테아린산마그네슘 0.6~0.9 중량%, 이산화규소 0.6~0.9 중량%, 히드록시프로필메틸 셀룰로오스 1.3~1.7 중량%, 카라멜 색소 1.3~1.7 중량%, 이산화티타늄 0.5~0.7 중량% 및 글리세린 0.1~0.3 중량%를 혼합한 혼합물일 수 있으며, 더욱 구체적으로는 수국차에 65%(v/v) 주정을 10배(v/w) 첨가한 후 60℃에서 2시간씩 2회 추출한 후 여과 및 농축하고 건조한 수국(Hydrangea macrophylla) 추출 분말 50 중량%, 결정 셀룰로오스 42.7 중량%, 유당 2 중량%, 스테아린산마그네슘 0.75 중량%, 이산화규소 0.75 중량%, 히드록시프로필메틸 셀룰로오스 1.5 중량%, 카라멜 색소 1.5 중량%, 이산화티타늄 0.6 중량% 및 글리세린 0.2 중량%를 혼합한 혼합물일 수 있다.In the hydrangea extract mixing composition of the present invention, the mixture is added specifically to the hydrangea tea at a rate of 8 to 12 times (v / w) at 60 to 70% (v / v) , 48 to 52% by weight of hydrangea macrophylla extract powder, 1 to 3 times of filtration, concentrated and dried, 40 to 45% by weight of crystalline cellulose, 1.8 to 2.2% by weight of lactose, 0.6 to 0.9% by weight of magnesium stearate, The mixture may be a mixture of 0.6 to 0.9 wt% of hydroxypropylmethylcellulose, 1.3 to 1.7 wt% of hydroxypropylmethylcellulose, 1.3 to 1.7 wt% of caramel colorant, 0.5 to 0.7 wt% of titanium dioxide and 0.1 to 0.3 wt% of glycerin, (V / v) of 65% (v / v) alcohol was added to the hydrangea tea, and the mixture was extracted twice at 60 ° C for 2 hours, then filtered and concentrated to obtain 50 wt.% Hydrangea macrophylla extract powder, 42.7% by weight of cellulose, 2% by weight of lactose, 0.75% by weight of magnesium stearate, 0.75% by weight of silicon dioxide, 1.5% by weight of ropil methyl cellulose, 1.5% by weight of caramel colorant, 0.6% by weight of titanium dioxide and 0.2% by weight of glycerin.

본 발명의 수국 추출 혼합 조성물은 좌측 전전두엽에서 RHB(Relative High Beta Power Spectrum)의 감소를 유도하여 긴장 및 집중 완화 효과를 나타내는 것을 특징으로 한다.The hydronephritic mixed composition of the present invention is characterized by exhibiting a relaxation and concentration-reducing effect by inducing a reduction of RHB (Relative High Beta Power Spectrum) in the left prefrontal cortex.

RHB는 전체에서 high beta파의 비율을 의미하는 것으로, beta파는 일반적인 작업을 하거나 의식적인 행동을 할 때 나타나며 정신활동이 있을 때 활성화되므로, beta파의 감소는 두뇌 상태를 안정화시키고 이완시켜 심리적으로 편안함을 증가시킨다. RHB refers to the proportion of high beta waves in the whole, where beta waves appear when doing normal work or conscious behavior and are activated when there is mental activity, so the reduction of beta waves stabilizes and relaxes the brain state, .

또한, 본 발명은 수국 추출 혼합 조성물을 포함하는 긴장 및 집중 완화용 건강기능식품을 제공한다.The present invention also provides a health functional food for stress and concentration alleviation comprising the hydrated extractive mixed composition.

상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. The health functional food may contain various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination.

본 발명의 건강기능식품은 여러가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The health functional food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.

본 발명은 또한,The present invention also relates to

(a) 수국차에 60~70%(v/v) 주정을 8~12배(v/w) 첨가한 후 50~70℃에서 1~3시간씩 1~3회 추출한 후 여과 및 농축하고 건조하여 수국(Hydrangea macrophylla) 추출 분말을 준비하는 단계; 및(a) 60 to 70% (v / v) alcohol was added to the water tea at 8 to 12 times (v / w) and then extracted 1 to 3 times at 50 to 70 ° C for 1 to 3 hours. Preparing Hydrangea macrophylla extract powder; And

(b) 수국 추출 혼합물 총 중량 기준으로, 상기 (a)단계의 준비한 수국 추출 분말 48~52 중량%와 결정 셀룰로오스 40~45 중량%, 유당 1.8~2.2 중량%, 스테아린산마그네슘 0.6~0.9 중량%, 이산화규소 0.6~0.9 중량%, 히드록시프로필메틸 셀룰로오스 1.3~1.7 중량%, 카라멜 색소 1.3~1.7 중량%, 이산화티타늄 0.5~0.7 중량% 및 글리세린 0.1~0.3 중량%를 혼합하는 단계를 포함하는 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물의 제조방법을 제공한다.(b) 48 to 52% by weight of hydrangea extract powder prepared in the step (a), 40 to 45% by weight of crystalline cellulose, 1.8 to 2.2% by weight of lactose, 0.6 to 0.9% by weight of magnesium stearate, Comprising mixing 0.6 to 0.9% by weight of silicon dioxide, 1.3 to 1.7% by weight of hydroxypropylmethylcellulose, 1.3 to 1.7% by weight of caramel dyes, 0.5 to 0.7% by weight of titanium dioxide and 0.1 to 0.3% by weight of glycerin, Provided is a method for producing a hydrangea extract mixture having a concentrated relaxation effect.

본 발명의 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물의 제조방법은, 보다 구체적으로는The method for producing the hydrangea extract mixture of the present invention having the effect of tautness and concentration alleviation, more specifically,

(a) 수국차에 65%(v/v) 주정을 10배(v/w) 첨가한 후 60℃에서 2시간씩 2회 추출한 후 여과 및 농축하고 건조하여 수국(Hydrangea macrophylla) 추출 분말을 준비하는 단계; 및(a) 65% to hydrangea tea (v / v) to 10 times ethanol (v / w) was added and then extracted twice with 60 ℃ for 2 hours, filtered and concentrated and dried hydrangea (Hydrangea macrophylla) preparing an extract powder ; And

(b) 수국 추출 혼합물 총 중량 기준으로, 상기 (a)단계의 준비한 수국 추출 분말 50 중량%와 결정 셀룰로오스 42.7 중량%, 유당 2 중량%, 스테아린산마그네슘 0.75 중량%, 이산화규소 0.75 중량%, 히드록시프로필메틸 셀룰로오스 1.5 중량%, 카라멜 색소 1.5 중량%, 이산화티타늄 0.6 중량% 및 글리세린 0.2 중량%를 혼합하는 단계를 포함할 수 있다.(b) extracting hydrangea powder comprising 50% by weight of the hydrated extract powder prepared in the step (a), 42.7% by weight of crystalline cellulose, 2% by weight lactose, 0.75% by weight magnesium stearate, 0.75% by weight silicon dioxide, 1.5% by weight of propyl methylcellulose, 1.5% by weight of caramel colorant, 0.6% by weight of titanium dioxide and 0.2% by weight of glycerin.

본 발명은 또한, 상기 방법으로 제조된 긴장 및 집중 완화 효과를 지니는 수국 추출 혼합물을 제공한다.
The present invention also provides a hydrangea extract mixture having the tautness and concentration alleviating effect produced by the above method.

이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

제조예Manufacturing example 1. 수국 추출 분말 제조 1. Manufacture of hydrangea extract powder

7월과 8월에 걸쳐 채취한 수국(Hydrangea macrophylla)의 잎을 햇빛에 잘 건조시키고, 수국 잎 각 부분의 수분함량을 균일하게 하고 세포조직을 적당히 파괴하여 포함된 성분이 추출 시 잘 우러나도록 수국의 녹색 잎이 암갈색이 될 때까지 유념기를 이용하여 비벼 말린 형태로 만드는 공정으로서 유념을 실시하였다. 상기 유념한 수국 잎을 밀폐 용기에 넣어 밀봉한 후, 37℃에서 12시간 동안 숙성한 후 햇볕에 완전히 건조하여 수국차를 제조하였다. Hydrangea macrophylla leaves were dried in the sunlight in July and August, the water content of each part of hydrangea leaves was uniformed, the cell tissue was properly destroyed, and hydrangea Was used as a process to make the green leaf in a dark brown color by using an observing machine. The noted hydrangea leaves were sealed in a sealed container, aged at 37 캜 for 12 hours, and dried thoroughly in the sun to prepare hydrangea tea.

상기 제조한 수국차 1 kg을 분쇄하고, 여기에 65% 주정 10 L를 넣고 60℃에서 2시간씩 2회 추출한 후 여과지(세공 0.7 마이크로미터)를 이용하여 감압 여과하였다. 상기 여과한 추출물을 50℃에서 16~18 기압 조건에서 농축시켜 농축액을 제조하였다. 상기 제조한 농축액에 농축액의 고형분 함량과 1:1 중량비율로 덱스트린을 녹인 후 분무 건조하였다.1 kg of the hydrangea tea prepared above was pulverized, 10 L of 65% ethanol was added thereto, and the mixture was extracted twice at 60 ° C for 2 hours, and then filtered under reduced pressure using a filter paper (pore 0.7 micrometer). The filtrate was concentrated at 50 to < RTI ID = 0.0 > 18 < / RTI > Dextrin was dissolved in the concentrate in a 1: 1 weight ratio with the solid content of the concentrate, followed by spray drying.

상기 제조한 수국 추출 분말을 메탄올에 녹여 HPLC로 분석하였을 때 유효성분인 툰베르기놀(thunberginol) C는 0.02% 이상인 것을 확인하였다(도 1).
When the hydronephric extract powder prepared above was dissolved in methanol and analyzed by HPLC, it was confirmed that the active ingredient, thunberginol C, was 0.02% or more (Fig. 1).

제조예Manufacturing example 2. 수국 추출 혼합물 제조 2. Manufacture of hydrangea extract mixture

제조예 1에서 얻은 수국 추출 분말 50 중량%와 결정 셀룰로오스 42.7 중량%, 유당 2 중량%, 스테아린산마그네슘 0.75 중량%, 이산화규소 0.75 중량%, 히드록시프로필메틸 셀룰로오스 1.5 중량%, 카라멜 색소 1.5 중량%, 이산화티타늄 0.6 중량%, 글리세린 0.2 중량%를 혼합하여 수국 추출 혼합물을 제조하였다.
A mixture of 50% by weight of the hydrated extract powder obtained in Preparation Example 1, 42.7% by weight of crystalline cellulose, 2% by weight lactose, 0.75% by weight magnesium stearate, 0.75% by weight silicon dioxide, 1.5% by weight hydroxypropylmethylcellulose, 1.5% by weight caramel colorant, 0.6% by weight of titanium dioxide and 0.2% by weight of glycerin were mixed to prepare a hydrangea extract mixture.

비교예Comparative Example 1. 수국 추출 혼합물 1. Hydrone extract mixture

(a) 현미배아 및 프락토올리고당을 94:5 중량비율로 혼합한 후 100℃에서 10~30분 동안 살균한 혼합물을 36℃ 이하로 냉각한 후, 상기 냉각한 혼합물에 황국균(Aspergillus oryzae)을 99:1 중량비율로 혼합한 후 멸균수를 첨가하여 36℃ 온도 및 상대습도 60%의 조건으로 48~96시간 동안 배양하였다. 상기 배양한 배양물을 45℃에서 6~10시간 동안 건조하여 수분함량이 8%(v/w) 이하가 되도록 건조하여 현미배아효소를 제조하였다.(a) a mixture of a brown rice embryo and a fructooligosaccharide in a weight ratio of 94: 5 and then sterilized at 100 ° C for 10 to 30 minutes was cooled to 36 ° C or lower, and then cooled to an Aspergillus oryzae were mixed in a weight ratio of 99: 1, sterilized water was added, and the mixture was incubated at 36 ° C. and 60% relative humidity for 48 to 96 hours. The cultured cultures were dried at 45 ° C for 6 to 10 hours, and dried to a moisture content of 8% (v / w) or less to prepare brown rice embryo enzymes.

(b) 수국 잎 25 중량%, 당귀 20 중량%, 상기 (a)단계의 제조한 현미배아효소 20 중량%, 황금 20 중량%, 오미자 10 중량% 및 하수오 5 중량%를 혼합하여 수국 혼합물을 준비하였다.(b) hydrangea blend was prepared by mixing 25% by weight of hydrangea leaves, 20% by weight of Angelica gigas, 20% by weight of the brown rice embryo enzyme prepared in step (a), 20% by weight of gold, 10% by weight of omija and 5% Respectively.

(c) 상기 (b)단계의 수국 혼합물을 추출포에 담고 물을 혼합물 중량 대비 10배량 첨가한 후 100℃ 온도 및 1~2 kgf/cm2의 압력에서 12시간 동안 추출하였다. 상기 추출한 추출물을 5 ㎛ 필터로 여과한 여과액을 감압농축기를 이용하여 60℃에서 고형분 함량이 20%(w/v)가 되도록 농축하였다. 상기 농축한 농축액을 분무건조기(열풍온도 180℃, 배풍온도 103℃, 디스크 속도 10,000 rpm)를 이용하여 분말화하여 수국추출분말을 제조하였다.(c) The hydrangea mixture of step (b) was added to the extract and water was added 10 times by weight of the mixture, and the mixture was extracted at a temperature of 100 ° C. and a pressure of 1 to 2 kgf / cm 2 for 12 hours. The extracted extract was filtered with a 5 탆 filter, and the filtrate was concentrated to a solid content of 20% (w / v) at 60 캜 by using a vacuum concentrator. The concentrated concentrate was pulverized using a spray drier (hot air temperature 180 占 폚, air temperature 103 占 폚, disk speed 10,000 rpm) to prepare hydrangea extract powder.

(d) 상기 (c)단계의 제조한 수국 추출 분말 35 중량%, 프락토올리고당 30.96 중량%, 말토덱스트린 25 중량%, 이노시톨 5 중량%, 타우린 2 중량%, 수국향 1 중량%, 효소처리스테비아 1 중량%, 비타민 B1 0.01 중량%, 비타민 B3 0.01 중량%, 비타민 B5 0.01 중량% 및 비타민 B6 0.01 중량%를 혼합하였다.
(d) the hydrolyzate extract powder prepared in the step (c), 35 wt% of fructooligosaccharide, 30 wt% of maltodextrin, 5 wt% of inositol, 2 wt% of taurine, 1% by weight of vitamin B1, 0.01% by weight of vitamin B1, 0.01% by weight of vitamin B3, 0.01% by weight of vitamin B5 and 0.01% by weight of vitamin B6.

비교예Comparative Example 2.  2. 산수국Mountain landscape 추출 혼합물 Extraction mixture

상기 제조예 2의 방법으로 추출 혼합물을 제조하되, 수국(Hydrangea macrophylla)을 사용하지 않고, 산수국(Hydrangea serrata)을 사용하여 산수국 추출 혼합물을 제조하였다.
The extract mixture was prepared by the method of Preparation Example 2, except that hydrangea macrophylla was not used, and Hydrangea serrata was used to prepare an extract of a mountain water soup.

실시예Example 1. 수국 추출 혼합물이 뇌파에 미치는 영향 분석 1. Effects of extractive hydration mixture on EEG

제조예 2의 수국 추출 혼합물의 섭취가 인간의 뇌 활동에 어떠한 영향을 주었는지를 알고자 뇌파를 측정하였다. 뇌파 측정은 최대한 잡음이 혼입되지 않은 온도 23℃, 습도 50%가 유지되는 32.4 m2 크기의 실험실에서 남, 녀 각각 10명 총 20명의 피험자를 대상으로 수행하였다. 뇌파측정을 위해 사용한 뇌파측정기는 QEEG-64FX 시스템(LAXTHA Inc. 한국)이었으며, 피험자의 뇌파신호 측정은 LAXTHA사의 데이터 수집 장비 및 분석 프로그램(Telescan)을 이용하였다. 피험자들에게 10~20 국제표준전극 부착법을 이용하여 좌측과 우측 전전두엽(Fp1, Fp2, Fpz, Af3, Af4, Afz), 좌측과 우측 전두엽(F3, F4, F7, F8, Fz, Fc1, Fc2, Fc5, Fc6), 좌측과 우측 측두엽(T3, T4, T7, T8, Cp5, Cp6), 좌측과 우측 두정엽(P3, P4, P7, P8, Cp1, Cp2, Cz, Pz), 좌측과 우측 후두엽(O1, O2, Oz) 부분에 부착하고 오른쪽과 왼쪽 귓불에도 각각 그라운드 및 레퍼런스 전극을 부착하였다(도 2 및 3). 피험자가 눈을 감은 상태에서 맹물 시음(무자극)과 수국 추출 혼합물 섭취(유자극)로 하여 각각 45초씩 측정하였다.The brain waves were measured in order to know how the intake of the hydrangea extract mixture of Preparation Example 2 affected human brain activity. EEG measurements were performed on a total of 20 subjects, 10 of each male and female, in a laboratory of 32.4 m 2 in which the noise was not mixed and the temperature was maintained at 23 ° C and 50% humidity. The EEG used for the EEG was a QEEG-64FX system (LAXTHA Inc. Korea). EEG signals were measured using LAXTHA's data collection equipment and analysis program (Telescan). The left and right prefrontal cords (Fp1, Fp2, Fpz, Af3, Af4, Afz), left and right frontal lobes (F3, F4, F7, F8, Fz, Fc1, Fc2, Left and right temporal lobes (P3, P4, P7, P8, Cp1, Cp2, Cz, Pz), left and right temporal lobes (T3, T4, T7, T8, Cp5, Cp6) O1, O2, and Oz), and ground and reference electrodes were attached to the right and left earlobes, respectively (FIGS. 2 and 3). Subjects were examined for 45 seconds with eyes closed (no irritation) and with hydrangea extract (dietary stimulation).

수국 추출 혼합물에 대한 뇌파측정을 통해 얻어진 데이터 처리는 피험자의 뇌파신호 중 대표적인 30초간의 뇌파신호만을 추출하여 뇌파일괄처리 프로그램(batch processing)으로 수행한 후, 통계분석 소프트웨어 프로그램인 SPSS(SPSS 23.0 version)를 이용하여 대응표본 T 검정을 수행하였다.The data processing obtained by the EEG extraction of the hydronephritic extract mixture was performed by extracting only a representative 30-second EEG signal among the EEG signals of the subject and performing an EEG batch processing. Then, the statistical analysis software program SPSS (SPSS 23.0 version ) Was used to perform a corresponding sample T test.

수국 추출 혼합물에 대한 데이터 분석을 위한 뇌파 지표의 종류는 표 1에, 그리고 각각의 뇌파 지표의 의미는 표 2에 나타내었다.Table 1 shows the types of EEG indices for data analysis of hydronephrine extract mixtures, and Table 2 shows the meanings of EEG indices.

데이터 분석에 사용된 뇌파 지표의 종류Types of EEG indicators used in data analysis No.No. 분석지표Analysis index 뇌파 분석 지표의 전체 이름Full name of EEG indicator 파장대(Hz)Waveband (Hz) 1One ATAT Absolute Theta Power SpectrumAbsolute Theta Power Spectrum 4~84 to 8 22 AAAA Absolute Alpha Power SpectrumAbsolute Alpha Power Spectrum 8~138-13 33 ABAB Absolute Beta Power SpectrumAbsolute Beta Power Spectrum 13~3013 to 30 44 AGAG Absolute Gamma Power SpectrumAbsolute Gamma Power Spectrum 30~5030 to 50 55 AFAAFA Absolute Fast Alpha Power SpectrumAbsolute Fast Alpha Power Spectrum 11~1311-13 66 ASAASA Absolute Slow Alpha Power SpectrumAbsolute Slow Alpha Power Spectrum 8~118 ~ 11 77 ALBALB Absolute Low Beta Power SpectrumAbsolute Low Beta Power Spectrum 12~1512 to 15 88 AMBAMB Absolute Mid Beta Power SpectrumAbsolute Mid Beta Power Spectrum 15~2015-20 99 AHBAHB Absolute High Beta Power SpectrumAbsolute High Beta Power Spectrum 20~3020 ~ 30 1010 RTRT Relative Theta Power SpectrumRelative Theta Power Spectrum (4~8)/(4~50)(4 to 8) / (4 to 50) 1111 RARA Relative Alpha Power SpectrumRelative Alpha Power Spectrum (8~13)/(4~50)(8 to 13) / (4 to 50) 1212 RBRB Relative Beta Power SpectrumRelative Beta Power Spectrum (13~30)/(4~50)(13 to 30) / (4 to 50) 1313 RGRG Relative Gamma Power SpectrumRelative Gamma Power Spectrum (30~50)/(4~50)(30 to 50) / (4 to 50) 1414 RFARFA Relative Fast Alpha Power SpectrumRelative Fast Alpha Power Spectrum (11~13)/(4~50)(11 to 13) / (4 to 50) 1515 RSARSA Relative Slow Alpha Power SpectrumRelative Slow Alpha Power Spectrum (8~11)/(4~50)(8 to 11) / (4 to 50) 1616 RLBRLB Relative Low Beta Power SpectrumRelative Low Beta Power Spectrum (12~15)/(4~50)(12 to 15) / (4 to 50) 1717 RMBRMB Relative Mid Beta Power SpectrumRelative Mid Beta Power Spectrum (15~20)/(4~50)(15 to 20) / (4 to 50) 1818 RHBRHB Relative High Beta Power SpectrumRelative High Beta Power Spectrum (20~30)/(4~50)(20 to 30) / (4 to 50) 1919 RSTRST Ratio of SMR to ThetaRatio of SMR to Theta (12~15)/(4~8)(12 to 15) / (4 to 8) 2020 RMTRMT Ratio of Mid Beta to ThetaRatio of Mid Beta to Theta (15~20)/(4~8)(15 to 20) / (4 to 8) 2121 RSMTRSMT Ratio of (SMR-Mid Beta) to ThetaRatio of (SMR-Mid Beta) to Theta (12~20)/(4~8)(12 to 20) / (4 to 8) 2222 RAHBRAHB Ratio of Alpha to High BetaRatio of Alpha to High Beta (8~13)/(20~30)(8 to 13) / (20 to 30) 2323 SEF50SEF50 Spectral Edge Frequency 50%Spectral Edge Frequency 50% 4~504 to 50 2424 SEF90SEF 90 Spectral Edge Frequency 90%Spectral Edge Frequency 90% 4~504 to 50 2525 ASEFASEF Spectral Edge Frequency 50% of Alpha Spectrum BandSpectral Edge Frequency 50% of Alpha Spectrum Band 8~138-13

데이터 분석에 사용된 뇌파 지표의 의미Meaning of EEG indices used in data analysis No.No. 분석지표Analysis index 의미meaning 1One ATAT Theta파의 절대파워 (명상, 졸릴때)Absolute power of theta wave (meditation, sleepy) 22 AAAA Alpha파의 절대파워 (이완, 안정)Absolute power of Alpha wave (relaxation, stability) 33 ABAB Beta파의 절대파워 (긴장, 각성, 활성, 인지작용)The absolute power of Beta waves (tension, arousal, activity, cognitive function) 44 AGAG Gamma파의 절대파워 (고도의 인지작용 또는 불안, 흥분)Absolute power of the Gamma wave (highly cognitive or anxious, excited) 55 AFAAFA Fast alpha파의 절대파워 (편안하면서 몰입)Fast alpha Absolute power of wave (comfortable and immersive) 66 ASAASA Slow alpha파의 절대파워 (이완)Absolute power of Slow alpha wave (relaxation) 77 ALBALB Low beta파의 절대파워, SMR파라고도 함 (주의나 경계)Absolute power of the low beta wave, SMR parameter (caution or boundary) 88 AMBAMB Mid beta파의 절대파워 (집중, 주의)Mid beta wave absolute power (concentration, attention) 99 AHBAHB High beta파의 절대파워 (스트레스, 정신부하, 긴장)High beta Absolute power (stress, mental load, tension) 1010 RTRT 전체 중 Theta파의 비율Percentage of theta waves in total 1111 RARA 전체 중 Alpha파의 비율The ratio of Alpha waves in total 1212 RBRB 전체 중 Beta파의 비율The ratio of Beta waves in total 1313 RGRG 전체 중 Gamma파의 비율Percentage of Gamma waves in total 1414 RFARFA 전체에서 Fast Alpha파의 비율The percentage of Fast Alpha waves in total 1515 RSARSA 전체에서 Slow Alpha파의 비율Slow Alpha ratio in all 1616 RLBRLB 전체에서 Low Beta파의 비율The ratio of Low Beta waves in total 1717 RMBRMB 전체에서 Mid Beta파의 비율Percentage of Mid Beta waves in total 1818 RHBRHB 전체에서 High Beta파의 비율The ratio of High Beta waves in total 1919 RSTRST SMR파/Theta파의 비율The ratio of SMR wave / Theta wave 2020 RMTRMT Mid Beta파/Theta파의 비율Mid Beta wave / Theta wave ratio 2121 RSMTRSMT SMR~Mid Beta파/Theta파 (뇌파집중지표)SMR ~ Mid Beta wave / Theta wave (EEG concentration indicator) 2222 RAHBRAHB Alpha파/High Beta파 (안정 및 이완도)Alpha wave / High Beta wave (stable and relaxed) 2323 SEF50SEF50 Median Frequency 뇌 활성도 (뇌파각성)Median Frequency Brain activity (EEG) 2424 SEF90SEF 90 Median Frequency 뇌 활성도 (정신부하, 스트레스)Median Frequency Brain activity (mental stress, stress) 2525 ASEFASEF Alpha파의 SEF50 (쾌적성: Fast Alpha파가 많음)Alpha SEF50 (Comfort: Fast Alpha wave)

본 실시예에서 수국 추출 혼합물에 대한 뇌파측정 결과, 25개의 뇌파분석 지표 중 RHB(Relative High Beta Power Spectrum) 지표에서만 통계적인 유의차가 있는 것을 나타났다(p<0.05). 나마지 24개의 파워 스펙트럼은 유의적인 차이가 나타나지 않았기 때문에 본 실시예에서는 기술하지 않았다.
In the present embodiment, EEG measurement results showed that there was a statistically significant difference only in RHB (Relative High Beta Power Spectrum) index among 25 EEG analysis indexes ( p <0.05). Since the power spectra of the twenty-four power amplifiers were not significantly different from each other, they were not described in this embodiment.

그 결과, 본 발명의 수국 추출 혼합물의 시음이 좌측 전전두엽의 Fp1 부위에서 RHB(relative high beta power spectrum)을 감소를 유도하여 긴장과 집중을 완화시키는 효과를 낸다는 것을 알 수 있었다(표 3).As a result, it was found that the tasting of the hydrangea extract mixture of the present invention resulted in reducing the relative high beta power spectrum (RHB) at the Fp1 site of the left prefrontal cortex, thereby relieving tension and concentration (Table 3).

Figure 112018119868017-pat00001
Figure 112018119868017-pat00001

실시예Example 2. 추출 혼합물의  2. Of the extraction mixture RHBRHB 파워 스펙트럼에 미치는 영향 Impact on Power Spectrum

제조예 1과 비교예들의 추출 혼합물의 섭취 후 RHB에 대한 변화를 관찰한 결과는 하기 표 4와 같다. 그 결과, 제조예 1의 수국 추출 혼합물은 Fp1 부위에서 RHB(Relative High Beta Power Spectrum) 지표를 감소하는 효과를 나타낸 반면(p<0.05), 비교예 1 및 비교예 2의 추출 혼합물은 모든 뇌 위치에서 RHB 지표에서는 영향을 주지 않음을 확인할 수 있었다.The results of observing changes in RHB after the ingestion of the extract mixture of Preparation Example 1 and Comparative Example are shown in Table 4 below. As a result, the hydrangea extract mixture of Preparation Example 1 showed an effect of reducing the Relative High Beta Power Spectrum (RHB) index at the Fp1 site ( p < 0.05), while the extract mixture of Comparative Example 1 and Comparative Example 2 showed all brain sites In the RHB index.

추출 혼합물의 RHB 파워 스펙트럼에 미치는 영향Effect of extraction mixture on RHB power spectrum 뇌 부위Brain area 제조예 1Production Example 1 비교예 1Comparative Example 1 비교예 2Comparative Example 2 Fp1Fp1 감소 ▼Decrease ▼ -- -- Fp2Fp2 -- -- -- F3F3 -- -- -- F4F4 -- -- -- T3T3 -- -- -- T4T4 -- -- -- P3P3 -- -- -- P4P4 -- -- -- O1O1 -- -- -- O2O2 -- -- -- F7F7 -- -- -- F8F8 -- -- -- T7T7 -- -- -- T8T8 -- -- -- P7P7 -- -- -- P8P8 -- -- -- AfzAfz -- -- -- CzCz -- -- -- FzFz -- -- -- PzPz -- -- -- FpzFpz -- -- -- OzOz -- -- -- Af3Af3 -- -- -- Af4Af4 -- -- -- Fc1Fc1 -- -- -- Fc2Fc2 -- -- -- Fc5Fc5 -- -- -- Fc6Fc6 -- -- -- Cp1Cp1 -- -- -- Cp2Cp2 -- -- -- Cp5Cp5 -- -- -- Cp6Cp6 -- -- --

Fp1/Af3: 좌측 전전두엽(left prefrontal), Fp2/Af4: 우측 전전두엽(Right prefrontal), Fpz/Afz: 중앙 전전두엽(Central prefrontal), F3/F7/Fc1/Fc5: 좌측 전두엽(Left frontal), F4/F8/Fc2/Fc6: 우측 전두엽(Right frontal), Fz: 중앙 전두엽(Contral frontal), T3/T7/Cp5: 좌측 측두엽(Left tomporal), T4/T8/Cp6: 우측 측두엽(Right temporal), P3/P7/Cp1: 좌측 두정엽(Left parietal), P4/P8/Cp2: 우측 두정엽(Right parietal), Cz/Pz: 중앙 두정엽(Central parietal), O1: 좌측 후두엽(Left occipital), O2: 우측 후두엽(Right occipital), Oz: 중앙 후두엽(Central occipital)Fp1 / Af3: Left prefrontal, Fp2 / Af4: Right prefrontal, Fpz / Afz: Central prefrontal, F3 / F7 / Fc1 / Fc5: Left frontal, F4 / T3 / T7 / Cp5: Left temporal, T4 / T8 / Cp6: Right temporal, P3 / T6 / Fc6: Right frontal, Fz: Central frontal, P4 / Cp1: Left parietal, P4 / P8 / Cp2: Right parietal, Cz / Pz: Central parietal, O1: Left occipital, O2: Right occipital (Right parietal) occipital), Oz: central occipital (Central occipital)

Claims (7)

건조한 후 유념한 수국 잎을 밀폐 용기에 넣어 밀봉한 후 37℃에서 12시간 동안 숙성하고 건조하여 제조한 수국차에 65%(v/v) 주정을 10배(v/w) 첨가한 후 60℃에서 2시간씩 2회 추출한 후 여과 및 50℃ 및 16~18기압에서 농축하고 분무 건조한 수국(Hydrangea macrophylla) 추출 분말 50 중량%, 결정 셀룰로오스 42.7 중량%, 유당 2 중량%, 스테아린산마그네슘 0.75 중량%, 이산화규소 0.75 중량%, 히드록시프로필메틸 셀룰로오스 1.5 중량%, 카라멜 색소 1.5 중량%, 이산화티타늄 0.6 중량% 및 글리세린 0.2 중량%를 혼합한 혼합물을 유효성분으로 함유하는 좌측 전전두엽에서 RHB(Relative High Beta Power Spectrum)를 감소시키는 긴장 및 집중 완화용 수국 추출 혼합 조성물.After drying, the hydrangea leaves were sealed in a sealed container, and the mixture was vigorously aged at 37 ° C for 12 hours. The hydrangea tea was added with 65% (v / v) vat 10 times (v / w) 50% by weight of extracted Hydrangea macrophylla powder, 42.7% by weight of crystalline cellulose, 2% by weight of lactose, 0.75% by weight of lactose, magnesium stearate, RHB (Relative High Beta Power) was added to the left prefrontal cortex containing 0.75% by weight of silicon dioxide, 1.5% by weight of hydroxypropylmethylcellulose, 1.5% by weight of caramel colorant, 0.6% by weight of titanium dioxide and 0.2% Spectrum. &Lt; / RTI &gt; 삭제delete 삭제delete 제1항에 따른 수국 추출 혼합 조성물을 포함하는 긴장 및 집중 완화용 건강기능식품.A health functional food for stress and intensive relaxation comprising the hydrated extractive mixed composition according to claim 1. 제4항에 있어서, 상기 조성물 이외에, 추가로 비타민, 광물, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 및 탄산음료에 사용되는 탄산화제 중에서 선택되는 하나 이상을 더 포함하는 것을 특징으로 하는 긴장 및 집중 완화용 건강기능식품.The composition according to claim 4, further comprising at least one compound selected from the group consisting of vitamins, minerals, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, And a carbonating agent used in a carbonated beverage. &Lt; Desc / Clms Page number 24 &gt; 삭제delete 삭제delete
KR1020180151614A 2018-11-30 2018-11-30 Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof KR101997023B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020180151614A KR101997023B1 (en) 2018-11-30 2018-11-30 Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180151614A KR101997023B1 (en) 2018-11-30 2018-11-30 Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof

Publications (1)

Publication Number Publication Date
KR101997023B1 true KR101997023B1 (en) 2019-07-05

Family

ID=67224978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180151614A KR101997023B1 (en) 2018-11-30 2018-11-30 Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof

Country Status (1)

Country Link
KR (1) KR101997023B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102221353B1 (en) * 2019-11-18 2021-03-02 대구한의대학교산학협력단 Composition comprising the extract of Campsis grandiflora and Hydrangea macrophylla for preventing or treating neuro degenerative disease
KR20210050187A (en) * 2019-10-28 2021-05-07 제주대학교 산학협력단 Composition comprising thunberginol C for preventing and treating of stress diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160081206A (en) * 2014-12-31 2016-07-08 (주)아모레퍼시픽 Aromatic composition containing extract of hydrangea serrata for psychological relaxation
KR20170078504A (en) * 2015-12-28 2017-07-07 제주대학교 산학협력단 Composition comprising extract of Hydrangeae Dulcis Folium for preventing and treating of stress diseases
KR101847375B1 (en) * 2017-08-28 2018-04-11 강원대학교산학협력단 Dandelion mixed extract composition for improving brain comfort when tasting and uses thereof
KR20180057515A (en) * 2016-11-22 2018-05-30 (주)백천바이오텍 Method for producing Hydrangea macrophylla tea having attention and concentration strengthening effect

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160081206A (en) * 2014-12-31 2016-07-08 (주)아모레퍼시픽 Aromatic composition containing extract of hydrangea serrata for psychological relaxation
KR20170078504A (en) * 2015-12-28 2017-07-07 제주대학교 산학협력단 Composition comprising extract of Hydrangeae Dulcis Folium for preventing and treating of stress diseases
KR20180057515A (en) * 2016-11-22 2018-05-30 (주)백천바이오텍 Method for producing Hydrangea macrophylla tea having attention and concentration strengthening effect
KR101847375B1 (en) * 2017-08-28 2018-04-11 강원대학교산학협력단 Dandelion mixed extract composition for improving brain comfort when tasting and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210050187A (en) * 2019-10-28 2021-05-07 제주대학교 산학협력단 Composition comprising thunberginol C for preventing and treating of stress diseases
KR102351324B1 (en) * 2019-10-28 2022-01-14 제주대학교 산학협력단 Composition comprising thunberginol C for preventing and treating of stress diseases
KR102221353B1 (en) * 2019-11-18 2021-03-02 대구한의대학교산학협력단 Composition comprising the extract of Campsis grandiflora and Hydrangea macrophylla for preventing or treating neuro degenerative disease

Similar Documents

Publication Publication Date Title
CN103549056B (en) A kind of relieving alcoholism and protecting liver cold tea
CN112369492A (en) Gel candy capable of calming heart, soothing nerves and improving sleep and preparation method thereof
KR101997023B1 (en) Hydrangea macrophylla extract mixed composition for relaxation and reducing concentration and uses thereof
CN102860549A (en) Functional beverage having functions of beautifying and detoxification and preparation method thereof
KR101922466B1 (en) Method for producing Hydrangea macrophylla tea having attention and concentration strengthening effect
KR101847375B1 (en) Dandelion mixed extract composition for improving brain comfort when tasting and uses thereof
CN113811320A (en) Plant composition, preparation method and application thereof
CN106821856A (en) A kind of seven black hair blackening cosmetic compositions and preparation method thereof
CN113559037B (en) Cassia seed compound collagen liposome and application thereof
KR101533673B1 (en) Perfume composition for expressing the fragrance of gardenia jasminoides Ellis for. Grandiflora Makino
KR101980599B1 (en) Mixed fermentation solution composition of Orostachys japonica and pine needle for enhancing attention and concentration and uses thereof
KR20190052958A (en) Aronia fermentation solution composition for relaxation and uses thereof
KR101654737B1 (en) A composition having extracts of trifoliate orange for release of hangover and manufacturing method thereof
KR101855741B1 (en) Mixed composition of β-carotene for relaxation and uses thereof
KR102342136B1 (en) Jaw-line correction cosmetic mask pack
CN110772456B (en) Miracle fruit leaf compound and application thereof in anti-melanin formation product
KR20140018699A (en) Method for manufacturing hair growth promotion/hair loss prevention shampoo.
CN105995711A (en) Fructus phyllanthi compound preparation and preparation method thereof
KR101877290B1 (en) Aroma composition with grape flavor containing essential oil of Schisandra chinensis and Angelica gigas for enhancing concentration state and uses thereof
CN107375374B (en) A kind of fermentation extraction method for the American ginseng extract that there is auxiliary to improve sleep effect
KR100512449B1 (en) The method for manufacturing of tea
EP3881854A1 (en) Composition comprising plant extract of genus fraxinus as active ingredient for preventing, alleviating, or treating sleep disorders
KR101997028B1 (en) Mixed composition of lactic acid bacteria for enhancing awakening and uses thereof
KR20150129461A (en) Sasa quelpaertensis nakai tea and manufacture method thereof
KR20210002221A (en) Red ginseng products containing noni and the process for the preparation thereof

Legal Events

Date Code Title Description
AMND Amendment
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant